This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
I am sorry that Dr. Whitby has taken exception to parts of the report which I made to the Council on Pharmacy and Chemistry concerning the experimental and clinical status of sulfapyridine (The Journal, February 11, p. 538). I have no desire to enter into a controversy with him over our respective views on the experimental effects of sulfapyridine, as such a course wastes time and effort and rarely serves a useful purpose. However, since Dr. Whitby feels that he has been misquoted, both as to the content of his work and as to the interpretations which he has derived from certain of his investigations, courtesy requires an answer.A rereading of Dr. Whitby's Bradshaw lecture (Lancet2:1095 [Nov. 12] 1938) still leads me to the belief that "experimental detail" is lacking in his report concerning the therapeutic efficiency of the drug in staphylococcic infections in
Long PH. SULFAPYRIDINE. JAMA. 1939;112(18):1850–1851. doi:10.1001/jama.1939.02800180074028
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: